Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (2162)	6/14/1999 4:15:00 AM
From: Dan Spillane	Read Replies (2) \| Respond to of 2539

What do these folks want? Americans have been eating all kinds of stuff starting in 1988, in cheese. If ten years of use after testing is not enough, then forget it -- no reasonable development cycle can be subjected to decades of testing for each new product. There's just about ZERO testing for other new foods and crops made in other ways. Re: Gene food escapes health tests

To: Anthony Wong who wrote (2162)	6/14/1999 9:29:00 AM
From: jopawa	Read Replies (1) \| Respond to of 2539

Monday June 14, 8:08 am Eastern Time Company Press Release SOURCE: G.D. Searle & Co. FDA's Friedman Joins Searle as Senior Vice President, Clinical Affairs CHICAGO, June 14 /PRNewswire/ -- Pharmaceutical company G. D. Searle & Co. today announced the appointment of Michael A. Friedman, M.D., as senior vice president, clinical affairs effective in July. Most recently, Dr. Friedman was at the U.S. Food and Drug Administration (FDA), serving in a variety of roles, including acting commissioner. Dr. Friedman will be responsible for directing strategy and implementation of clinical research. He will support the management of Searle's entire portfolio of clinical research products, and expedite the development of novel, value-added therapeutics. In addition, he will advise and facilitate the development of novel nutritional product candidates within the Monsanto Life Sciences program. In addition to his role as FDA acting commissioner, Dr. Friedman also served as lead deputy commissioner and deputy operations commissioner for the agency. Prior to joining the FDA, Dr. Friedman spent 12 years at the National Cancer Institute, directing cancer research and therapy programs, and eight years on faculty at the University of California, San Francisco Medical School. Board certified in internal medicine and medical oncology, Dr. Friedman completed his medical internship and oncology fellowship at Stanford University Hospital. Dr. Friedman graduated from the University of Texas, Southwestern Medical School. He currently serves on the Board of Governors of the Armed Services Institute of Pathology. Dr. Friedman's appointment follows the retirement of John C. Alexander, M.D., who, since 1991, has led Searle's worldwide clinical trial development programs. The most recent clinical development success resulted in the December 1998 approval of Celebrex(TM), the most successful new drug launch in pharmaceutical history, with more than five million prescriptions written to date. ''We are delighted to welcome Dr. Friedman to Searle,'' said Philip Needleman, Ph.D., co-president, Searle, and chief scientist, Monsanto. Searle is the pharmaceutical sector of Monsanto Company (NYSE: MTC - news). Searle develops, produces and markets prescription pharmaceuticals, including major products to treat arthritis, cardiovascular disease, cancer and its complications and insomnia, and to promote women's health. For more information on Searle, access searlehealthnet.com. As a life sciences company, Monsanto is committed to finding solutions to the growing global needs for food and health by sharing common forms of science and technology among agriculture, nutrition and health. In 1998, Monsanto reported sales of $8.6 billion and invested approximately $1 billion in research and development. SOURCE: G.D. Searle & Co. -------------------------------------------------------------------------------- More Quotes and News: MONSANTO CO (NYSE:MTC - news) Related News Categories: chemicals, health care, medical/pharmaceutical -------------------------------------------------------------------------------- Help -------------------------------------------------------------------------------- Copyright © 1999 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. See our Important Disclaimers and Legal Information. Questions or Comments?